Voltar
Editorial Acesso aberto Revisado por pares
BIBTEX RIS

Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: the pathologists' perspective

2021; Elsevier BV; Volume: 32; Issue: 11 Linguagem: Inglês

10.1016/j.annonc.2021.08.1993

ISSN

1569-8041

Autores

Roberto Salgado, Vicente Peg, J. Rüschoff, Anne Vincent‐Salomon, Isabella Castellano, Sven Perner, Koen Van de Vijver, Cecily Quinn, Zsuzsanna Varga,

Tópico(s)

HER2/EGFR in Cancer Research

Resumo

Recommendations regarding the administration of adjuvant systemic treatment to patients with invasive breast carcinoma (BC) rely on the morphological assessment of key histopathological indices, including tumor subtype, size, histological grade, lymphovascular invasion, and lymph node status combined with estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 receptor (HER2) biomarker profile determined using immunohistochemistry (IHC) and in situ hybridization (ISH).

Referência(s)